Cancer Biologynpj Precision OncologyPeer-reviewed
TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers
R. Thawani, M. Repetto, C. Keddy…·M. A. Davare
This study shows that type II TKIs cabozantinib and merestinib, and type I FLT3 inhibitor gilteritinib, inhibit ROS1 L2086F mutant kinase, overcoming resistance to type I TKIs in ROS1 fusion-positive cancers.
DOI 10.1038/s41698-024-00663-1